Company Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.
The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 254 |
| CEO | Grant E. Pickering M.B.A. |
Contact Details
Address: 825 Industrial Road, Ste. 300 San Carlos, California 94070 United States | |
| Phone | 650-837-0111 |
| Website | vaxcyte.com |
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| Employer ID | 46-4233385 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer and Director |
| Andrew L. Guggenhime M.B.A. | President and Chief Financial Officer |
| James Wassil M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| Paul W. Sauer M.B.A. | Senior Vice President of Process Development and Manufacturing |
| Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder |
| Dr. Jeff Fairman Ph.D. | Co-Founder and Vice President of Research |
| Elvia Cowan | Senior Vice President of Finance and Principal Accounting Officer |
| Janet Graesser | Senior Vice President of Corporate Communications and Investor Relations |
| Whitney Jones | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 144 | Filing |
| Apr 18, 2024 | 144 | Filing |
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Mar 25, 2024 | 144 | Filing |
| Mar 18, 2024 | 144 | Filing |